<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Molecular effects of inhaled glucocorticoid therapy in asthma</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Molecular effects of inhaled glucocorticoid therapy in asthma</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Molecular effects of inhaled glucocorticoid therapy in asthma</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Peter J Barnes, DM, DSc, FRCP, FRS</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Bruce S Bochner, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Robert A Wood, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Paul Dieffenbach, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Mar 21, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Inhaled glucocorticoids (ie, glucocorticosteroids, corticosteroids, steroids) suppress airway inflammation by activating anti-inflammatory genes, switching off inflammatory gene expression, and inhibiting inflammatory cells. In addition, they enhance beta 2 adrenergic signaling by increasing beta 2-receptor expression and function. The net effect is control of the symptoms and signs of asthma in most patients.</p><p>The molecular effects of inhaled glucocorticoids in asthmatic airways are discussed in this topic review. In addition, the molecular determinants of glucocorticoid sensitivity are reviewed. The pharmacology of glucocorticoids, the role of inhaled glucocorticoids in the management of asthma, and the potential adverse effects of inhaled glucocorticoids are presented separately. (See  <a class="medical medical_review" href="/z/d/html/124.html" rel="external">"Pharmacologic use of glucocorticoids"</a> and  <a class="medical medical_review" href="/z/d/html/7976.html" rel="external">"Determinants of glucocorticoid dosing"</a> and  <a class="medical medical_review" href="/z/d/html/547.html" rel="external">"An overview of asthma management"</a> and  <a class="medical medical_review" href="/z/d/html/90904.html" rel="external">"Asthma in children younger than 12 years: Overview of initiating therapy and monitoring control"</a> and  <a class="medical medical_review" href="/z/d/html/549.html" rel="external">"Mechanisms and clinical implications of glucocorticoid resistance in asthma"</a> and  <a class="medical medical_review" href="/z/d/html/540.html" rel="external">"Major side effects of inhaled glucocorticoids"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">SUPPRESSION OF INFLAMMATION</span><span class="headingEndMark"> — </span>Discoveries related to gene transcription have improved our understanding of the mechanisms by which inhaled glucocorticoids suppress airway inflammation [<a href="#rid1">1,2</a>]. These mechanisms include anti-inflammatory gene activation and switching off inflammatory gene expression, which alter the expression of inflammatory and anti-inflammatory enzymes, receptors, cytokines, adhesion molecules, and chemokines. The net effect is decreased inflammatory cell recruitment, survival, and accumulation.</p><p class="headingAnchor" id="H3"><span class="h2">Anti-inflammatory gene activation</span><span class="headingEndMark"> — </span>There are two types of glucocorticoid receptors (GR), GR alpha and GR beta. Glucocorticoid action is facilitated by GR alpha, but potentially inhibited by GR beta.</p><p class="bulletIndent1"><span class="glyph">●</span>GR alpha – Glucocorticoids passively diffuse across the cell membrane and bind to GR alpha in the cytoplasm [<a href="#rid2">2</a>]. The glucocorticoid/GR alpha complex (ie, activated GR) rapidly translocates into the nucleus. There, the activated GR form dimers, which bind to glucocorticoid response elements (GREs) within the promoter of glucocorticoid-responsive genes. There are positive and negative GREs.</p><p></p><p class="bulletIndent1">Interaction with positive GREs stimulates gene transcription. Such genes usually encode anti-inflammatory proteins [<a href="#rid3">3</a>]. As an example, glucocorticoids stimulate expression of secretory leukoprotease inhibitor and mitogen-activated protein kinase phosphatase-1 (MKP-1), which inhibit mitogen-activated protein (MAP) kinase pathways (<a class="graphic graphic_figure graphicRef78772" href="/z/d/graphic/78772.html" rel="external">figure 1</a>) [<a href="#rid4">4</a>]. Interaction with positive GREs appears to account for most of the side effects of glucocorticoids [<a href="#rid5">5</a>]. As an example, binding the GR to the promoter site on the osteocalcin gene interferes with its transcription, resulting in reduced expression and reduction in bone synthesis.</p><p></p><p class="bulletIndent1">Interaction with negative GREs suppresses gene transcription, but there are only a few examples of reduced expression of inflammatory genes through interaction with negative GREs, indicating that other molecular mechanisms are involved in the suppression of inflammation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>GR beta – GR beta is an alternatively spliced form of GR. It binds DNA, but not glucocorticoids. As a result, GR beta may act as an inhibitor of glucocorticoid action by antagonizing the binding of GR alpha dimers to DNA, although the amounts of GR beta are thought to be too small to cause significant inhibition of glucocorticoid effects [<a href="#rid6">6</a>].</p><p></p><p class="headingAnchor" id="H4"><span class="h2">Switching off inflammatory genes</span><span class="headingEndMark"> — </span>In all inflammatory diseases, including asthma, many inflammatory genes are activated. These include genes that encode cytokines, chemokines, adhesion molecules, inflammatory enzymes, and receptors. Such genes are switched on when a coactivator molecule (eg, CREB-binding protein) binds to a proinflammatory transcription factor (eg, nuclear factor-kappa B [NF-kB], activator protein-1 [AP-1]). The coactivator molecule then acetylates core histones, which opens the chromatin structure and allows transcription to proceed [<a href="#rid7">7</a>].</p><p>There are several ways in which inhaled glucocorticoids interfere with this process and switch off the inflammatory cascade:</p><p class="bulletIndent1"><span class="glyph">●</span>Glucocorticoids interact with the coactivator molecules and inhibit their binding to proinflammatory transcription factors [<a href="#rid1">1,8</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Activated GR recruit histone deacetylase-2 (HDAC2), which deacetylates core histones. HDAC2 has broad impact, suppressing all activated inflammatory genes within the nucleus (<a class="graphic graphic_figure graphicRef59432" href="/z/d/graphic/59432.html" rel="external">figure 2</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>GR is normally acetylated and binds to DNA in its acetylated form. It has to be deacetylated by HDAC2 in order to inhibit NF-kB [<a href="#rid9">9</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>GR is translocated into the nucleus via the nuclear import protein importin-alpha [<a href="#rid10">10</a>]. The transcription factor GATA3 in T-helper 2 (Th2) lymphocytes regulates the expression of Th2 cytokines (interleukin [IL]-4, IL-5, and IL-13), which orchestrate allergic inflammation. GATA3 is also imported into the nucleus via importin-alpha, but activated GR takes precedence, preventing the nuclear import of GATA3, and thus rapidly inhibiting the expression of Th2 cytokines and suppressing allergic inflammation [<a href="#rid11">11</a>].</p><p></p><p>Regardless of the mechanism, the net effect is reduced histone acetylation, failure of the chromatin structure to open, and decreased transcription of inflammatory genes. Inhaled glucocorticoids preferentially impact inflammatory genes and do so primarily on a local level. Thus, they are effective at controlling asthma and are associated with few adverse effects.</p><p>There may also be post-transcriptional mechanisms by which glucocorticoids switch off inflammation. As an example, some inflammatory genes (eg, granulocyte-macrophage colony stimulating factor) normally have an unstable messenger RNA that is rapidly degraded by RNAses. Inflammatory mediators stabilize this messenger RNA during inflammation. Glucocorticoids reverse this effect, allowing rapid degradation of mRNA and reduced inflammatory protein secretion [<a href="#rid12">12</a>]. The mechanism of action is uncertain, but may be glucocorticoid-mediated inhibition of the proteins that stabilize mRNAs, such as tristetraprolin [<a href="#rid13">13</a>].</p><p>Further research is needed to determine which mechanisms are relevant in patients with asthma. There have been past examples of glucocorticoid-mediated effects that were detected experimentally, but could not subsequently be confirmed in patients. Specifically, the activated GR directly interacts with transcription factors and inhibits their activity in experimental systems, but not in patients with asthma [<a href="#rid14">14</a>].</p><p>Additionally, some effects of glucocorticoids may be mediated through non-genomic effects that are GR-independent and not blocked by the GR antagonist RU486 [<a href="#rid15">15</a>]. These responses include rapid effects on calcium signaling, apoptosis of inflammatory cells, and endothelial nitric oxide synthase, but whether these are relevant to the action of glucocorticoids in airway disease is uncertain.</p><p class="headingAnchor" id="H5"><span class="h2">Inflammatory cell inhibition</span><span class="headingEndMark"> — </span>By activating anti-inflammatory genes and switching off inflammatory gene expression, inhaled glucocorticoids inhibit inflammatory cell survival and suppress production of chemotactic mediators and adhesion molecules. The net effect is decreased mucosal inflammation, which is characterized by fewer inflammatory cells, including T lymphocytes, eosinophils, mast cells, and dendritic cells (<a class="graphic graphic_figure graphicRef70776" href="/z/d/graphic/70776.html" rel="external">figure 3</a>).</p><p>Suppression of mucosal inflammation begins within hours of administration [<a href="#rid16">16,17</a>]. As an example, in a double-blind crossover trial, 41 adults with stable asthma and at least 7 percent sputum eosinophilia were randomly assigned to receive a single dose of inhaled <a class="drug drug_general" data-topicid="9167" href="/z/d/drug information/9167.html" rel="external">budesonide</a> or placebo on two consecutive days [<a href="#rid16">16</a>]. Budesonide decreased sputum eosinophilia within six hours.</p><p>Decreased airway inflammation is associated with decreased airway responsiveness, which also begins within hours of inhaled glucocorticoid administration [<a href="#rid16">16-18</a>]. As an example, in three randomized, controlled crossover trials, <a class="drug drug_general" data-topicid="8951" href="/z/d/drug information/8951.html" rel="external">fluticasone</a> decreased airway responsiveness two- to three-fold within two hours [<a href="#rid17">17</a>]. This effect may gradually increase over several months before reaching a plateau [<a href="#rid18">18</a>].</p><p class="headingAnchor" id="H6"><span class="h1">BETA 2-RECEPTOR EFFECTS</span><span class="headingEndMark"> — </span>Suppression of airway inflammation is not the only way in which inhaled glucocorticoids reduce the symptoms and signs of asthma. They also enhance beta 2 adrenergic signaling by increasing beta 2-receptor expression and function.</p><p>Inhaled beta 2-agonists and glucocorticoids are frequently used together in the management of asthma. It is now recognized that there are important molecular interactions between these two classes of medication [<a href="#rid19">19,20</a>]. Specifically, glucocorticoids increase transcription of the gene encoding beta 2-receptors, inducing increased expression of beta 2-receptors on the cell surface [<a href="#rid21">21,22</a>]. They also enhance the coupling of beta 2-receptors to G-proteins. Taken together, these actions have the following impact:</p><p class="bulletIndent1"><span class="glyph">●</span>Increased beta 2-agonist effects (eg, mast cell stabilization)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Protection from the down-regulation of beta 2-receptors that is associated with long-term beta 2-agonist administration [<a href="#rid23">23</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Reversal or prevention of the uncoupling of beta 2-receptors from G proteins, which is induced by some inflammatory mediators (eg, interleukin-1 beta) [<a href="#rid24">24</a>]</p><p></p><p>In a reciprocal manner, beta 2-agonists influence the activated glucocorticoid receptors (GR). Specifically, beta 2-agonists increase translocation of the activated GR from the cytoplasm to the nucleus, which enhances the anti-inflammatory effects of glucocorticoids [<a href="#rid25">25</a>]. This has been demonstrated in the sputum macrophages of patients with asthma following administration of an inhaled glucocorticoid plus an inhaled long-acting beta 2-agonist [<a href="#rid26">26</a>].</p><p class="headingAnchor" id="H7"><span class="h1">GLUCOCORTICOID SENSITIVITY</span><span class="headingEndMark"> — </span>Some patients (usually with severe asthma) fail to respond to glucocorticoids, both inhaled and systemic. Such "steroid resistant" asthma may be due to reduced anti-inflammatory actions of glucocorticoids, rather than impaired absorption, increased metabolism, or poor compliance. (See  <a class="medical medical_review" href="/z/d/html/549.html" rel="external">"Mechanisms and clinical implications of glucocorticoid resistance in asthma"</a>.)</p><p>The ratio of GR alpha (which facilitates glucocorticoid action) to GR beta (which inhibits glucocorticoid action) can be altered by changing the expression GR alpha, GR beta, or both. In glucocorticoid sensitive cells the ratio tends to be higher, whereas in glucocorticoid resistant cells the ratio tends to be lower [<a href="#rid6">6</a>]. However, there is little evidence that decreases in the ratio of GR alpha to GR beta reduce glucocorticoid responsiveness because the amount of GR beta is too small to influence GR action. Other molecular mechanisms are more likely to account for glucocorticoid resistance in asthma [<a href="#rid27">27,28</a>].</p><p class="headingAnchor" id="H8"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical use</strong> – Inhaled glucocorticoids are potent suppressors of inflammation in the airways. They effectively control the symptoms and signs of asthma. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Molecular effects in the airways</strong> – The success of inhaled glucocorticoids in controlling the symptoms and signs of asthma is the net result of many favorable effects in the airways. These effects include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Anti-inflammatory gene activation and switching off inflammatory gene expression, which combine to inhibit inflammatory cells infiltration and survival in the airways. (See <a class="local">'Suppression of inflammation'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Increased expression of beta 2-receptors and enhanced coupling of beta 2-receptors to G-proteins, which combine to increase beta 2 adrenergic signaling. (See <a class="local">'Beta 2-receptor effects'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Glucocorticoid sensitivity</strong> – Glucocorticoid resistant asthma is most commonly due to reduced anti-inflammatory actions of glucocorticoids, rather than impaired absorption, increased metabolism, or poor compliance. (See <a class="local">'Glucocorticoid sensitivity'</a> above and  <a class="medical medical_review" href="/z/d/html/549.html" rel="external">"Mechanisms and clinical implications of glucocorticoid resistance in asthma"</a>.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Barnes PJ. Glucocorticosteroids: current and future directions. Br J Pharmacol 2011; 163:29.</a></li><li><a class="nounderline abstract_t">Oakley RH, Cidlowski JA. The biology of the glucocorticoid receptor: new signaling mechanisms in health and disease. J Allergy Clin Immunol 2013; 132:1033.</a></li><li><a class="nounderline abstract_t">Barnes PJ. Corticosteroid effects on cell signalling. Eur Respir J 2006; 27:413.</a></li><li><a class="nounderline abstract_t">Clark AR. MAP kinase phosphatase 1: a novel mediator of biological effects of glucocorticoids? J Endocrinol 2003; 178:5.</a></li><li><a class="nounderline abstract_t">Dostert A, Heinzel T. Negative glucocorticoid receptor response elements and their role in glucocorticoid action. Curr Pharm Des 2004; 10:2807.</a></li><li><a class="nounderline abstract_t">Lewis-Tuffin LJ, Cidlowski JA. The physiology of human glucocorticoid receptor beta (hGRbeta) and glucocorticoid resistance. Ann N Y Acad Sci 2006; 1069:1.</a></li><li><a class="nounderline abstract_t">Barnes PJ, Adcock IM, Ito K. Histone acetylation and deacetylation: importance in inflammatory lung diseases. Eur Respir J 2005; 25:552.</a></li><li><a class="nounderline abstract_t">Ito K, Barnes PJ, Adcock IM. Glucocorticoid receptor recruitment of histone deacetylase 2 inhibits interleukin-1beta-induced histone H4 acetylation on lysines 8 and 12. Mol Cell Biol 2000; 20:6891.</a></li><li><a class="nounderline abstract_t">Ito K, Yamamura S, Essilfie-Quaye S, et al. Histone deacetylase 2-mediated deacetylation of the glucocorticoid receptor enables NF-kappaB suppression. J Exp Med 2006; 203:7.</a></li><li><a class="nounderline abstract_t">Barnes PJ. Role of GATA-3 in allergic diseases. Curr Mol Med 2008; 8:330.</a></li><li><a class="nounderline abstract_t">Maneechotesuwan K, Yao X, Ito K, et al. Suppression of GATA-3 nuclear import and phosphorylation: a novel mechanism of corticosteroid action in allergic disease. PLoS Med 2009; 6:e1000076.</a></li><li><a class="nounderline abstract_t">Bergmann MW, Staples KJ, Smith SJ, et al. Glucocorticoid inhibition of granulocyte macrophage-colony-stimulating factor from T cells is independent of control by nuclear factor-kappaB and conserved lymphokine element 0. Am J Respir Cell Mol Biol 2004; 30:555.</a></li><li><a class="nounderline abstract_t">Brook M, Tchen CR, Santalucia T, et al. Posttranslational regulation of tristetraprolin subcellular localization and protein stability by p38 mitogen-activated protein kinase and extracellular signal-regulated kinase pathways. Mol Cell Biol 2006; 26:2408.</a></li><li><a class="nounderline abstract_t">Hart L, Lim S, Adcock I, et al. Effects of inhaled corticosteroid therapy on expression and DNA-binding activity of nuclear factor kappaB in asthma. Am J Respir Crit Care Med 2000; 161:224.</a></li><li><a class="nounderline abstract_t">Panettieri RA, Schaafsma D, Amrani Y, et al. Non-genomic Effects of Glucocorticoids: An Updated View. Trends Pharmacol Sci 2019; 40:38.</a></li><li><a class="nounderline abstract_t">Gibson PG, Saltos N, Fakes K. Acute anti-inflammatory effects of inhaled budesonide in asthma: a randomized controlled trial. Am J Respir Crit Care Med 2001; 163:32.</a></li><li><a class="nounderline abstract_t">Ketchell RI, Jensen MW, Lumley P, et al. Rapid effect of inhaled fluticasone propionate on airway responsiveness to adenosine 5'-monophosphate in mild asthma. J Allergy Clin Immunol 2002; 110:603.</a></li><li><a class="nounderline abstract_t">Juniper EF, Kline PA, Vanzieleghem MA, et al. Long-term effects of budesonide on airway responsiveness and clinical asthma severity in inhaled steroid-dependent asthmatics. Eur Respir J 1990; 3:1122.</a></li><li><a class="nounderline abstract_t">Barnes PJ. Scientific rationale for inhaled combination therapy with long-acting beta2-agonists and corticosteroids. Eur Respir J 2002; 19:182.</a></li><li><a class="nounderline abstract_t">Newton R, Giembycz MA. Understanding how long-acting β2 -adrenoceptor agonists enhance the clinical efficacy of inhaled corticosteroids in asthma - an update. Br J Pharmacol 2016; 173:3405.</a></li><li><a class="nounderline abstract_t">Mak JC, Nishikawa M, Barnes PJ. Glucocorticosteroids increase beta 2-adrenergic receptor transcription in human lung. Am J Physiol 1995; 268:L41.</a></li><li><a class="nounderline abstract_t">Baraniuk JN, Ali M, Brody D, et al. Glucocorticoids induce beta2-adrenergic receptor function in human nasal mucosa. Am J Respir Crit Care Med 1997; 155:704.</a></li><li><a class="nounderline abstract_t">Mak JC, Nishikawa M, Shirasaki H, et al. Protective effects of a glucocorticoid on downregulation of pulmonary beta 2-adrenergic receptors in vivo. J Clin Invest 1995; 96:99.</a></li><li><a class="nounderline abstract_t">Mak JC, Chuang TT, Harris CA, Barnes PJ. Increased expression of G protein-coupled receptor kinases in cystic fibrosis lung. Eur J Pharmacol 2002; 436:165.</a></li><li><a class="nounderline abstract_t">Roth M, Johnson PR, Rüdiger JJ, et al. Interaction between glucocorticoids and beta2 agonists on bronchial airway smooth muscle cells through synchronised cellular signalling. Lancet 2002; 360:1293.</a></li><li><a class="nounderline abstract_t">Usmani OS, Ito K, Maneechotesuwan K, et al. Glucocorticoid receptor nuclear translocation in airway cells after inhaled combination therapy. Am J Respir Crit Care Med 2005; 172:704.</a></li><li><a class="nounderline abstract_t">Barnes PJ, Adcock IM. Glucocorticoid resistance in inflammatory diseases. Lancet 2009; 373:1905.</a></li><li><a class="nounderline abstract_t">Barnes PJ. Corticosteroid resistance in patients with asthma and chronic obstructive pulmonary disease. J Allergy Clin Immunol 2013; 131:636.</a></li></ol></div><div id="topicVersionRevision">Topic 548 Version 16.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21198556" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Glucocorticosteroids: current and future directions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24084075" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : The biology of the glucocorticoid receptor: new signaling mechanisms in health and disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16452600" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Corticosteroid effects on cell signalling.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12844330" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : MAP kinase phosphatase 1: a novel mediator of biological effects of glucocorticoids?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15379669" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Negative glucocorticoid receptor response elements and their role in glucocorticoid action.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16855130" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : The physiology of human glucocorticoid receptor beta (hGRbeta) and glucocorticoid resistance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15738302" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Histone acetylation and deacetylation: importance in inflammatory lung diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10958685" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Glucocorticoid receptor recruitment of histone deacetylase 2 inhibits interleukin-1beta-induced histone H4 acetylation on lysines 8 and 12.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16380507" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Histone deacetylase 2-mediated deacetylation of the glucocorticoid receptor enables NF-kappaB suppression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18691059" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Role of GATA-3 in allergic diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19436703" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Suppression of GATA-3 nuclear import and phosphorylation: a novel mechanism of corticosteroid action in allergic disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14527927" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Glucocorticoid inhibition of granulocyte macrophage-colony-stimulating factor from T cells is independent of control by nuclear factor-kappaB and conserved lymphokine element 0.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16508015" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Posttranslational regulation of tristetraprolin subcellular localization and protein stability by p38 mitogen-activated protein kinase and extracellular signal-regulated kinase pathways.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10619824" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Effects of inhaled corticosteroid therapy on expression and DNA-binding activity of nuclear factor kappaB in asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30497693" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Non-genomic Effects of Glucocorticoids: An Updated View.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11208622" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Acute anti-inflammatory effects of inhaled budesonide in asthma: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12373268" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Rapid effect of inhaled fluticasone propionate on airway responsiveness to adenosine 5'-monophosphate in mild asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2090474" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Long-term effects of budesonide on airway responsiveness and clinical asthma severity in inhaled steroid-dependent asthmatics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11843317" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Scientific rationale for inhaled combination therapy with long-acting beta2-agonists and corticosteroids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27646470" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Understanding how long-actingβ2 -adrenoceptor agonists enhance the clinical efficacy of inhaled corticosteroids in asthma - an update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7840227" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Glucocorticosteroids increase beta 2-adrenergic receptor transcription in human lung.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9032216" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Glucocorticoids induce beta2-adrenergic receptor function in human nasal mucosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7615841" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Protective effects of a glucocorticoid on downregulation of pulmonary beta 2-adrenergic receptors in vivo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11858796" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Increased expression of G protein-coupled receptor kinases in cystic fibrosis lung.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12414205" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Interaction between glucocorticoids and beta2 agonists on bronchial airway smooth muscle cells through synchronised cellular signalling.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15860753" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Glucocorticoid receptor nuclear translocation in airway cells after inhaled combination therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19482216" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Glucocorticoid resistance in inflammatory diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23360759" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Corticosteroid resistance in patients with asthma and chronic obstructive pulmonary disease.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
